Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Anal Cancer Marketed and Pipeline Drugs Report Overview
Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition.
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Anal Cancer Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for anal cancer.
The report also provides actionable insights on the clinical and commercial landscapes of anal cancer drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Receptor Antagonist
· Cytotoxic to Cell · Enzyme Inhibitor · Receptor Agonist · Enzyme Activator |
Key Molecule Types (Pipeline) | · Biologics
· Small Molecules |
Key Routes of Administration (Pipeline) | · Injection
· Oral · Topical |
Top Sponsors (Marketed and Pipeline Drugs) | · National Cancer Institute, The US
· Merck & Co Inc. · Incyte Corp. · Molecular Partners AG · Xencor Inc. |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Anal Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the anal cancer pipeline mainly includes receptor antagonists, cytotoxic to cell, enzyme inhibitor, receptor agonist, and enzyme activator among others. Most of the drugs followed receptor antagonists MoA in 2023 in the anal cancer market.
Anal Cancer Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Anal Cancer Pipeline Drugs
Anal Cancer Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the anal cancer pipeline mainly includes injection, oral, and topical. Most pipeline drugs that were under development for anal cancer were injection therapies in 2023.
Anal Cancer Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Anal Cancer Pipeline Drugs
Anal Cancer Pipeline Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for anal cancer pipeline drugs was biologics. It was followed by small molecules.
Anal cancer Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Anal Cancer Pipeline Drugs
Anal Cancer Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in anal cancer marketed and pipeline drugs market are National Cancer Institute, the US, Merck & Co Inc., Incyte Corp., Molecular Partners AG, and Xencor Inc., among others. the National Cancer Institute sponsored the highest number of drugs in 2023. However, within commercial sponsors, most of the completed trials conducted in the anal cancer space over the past 10 years were sponsored by pharma companies such as Merck and Incyte Corp.
Anal Cancer Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Anal Cancer Marketed and Pipeline Drugs Market
Segments Covered in the Report
Anal Cancer Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Antagonist
- Cytotoxic to Cell
- Receptor Agonist
- Enzyme Activator
- Enzyme Inhibitor
Anal Cancer Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the anal cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global anal cancer market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for anal cancer pipeline drugs in 2023?
Most of the drugs followed receptor antagonists MoA in 2023 in the anal cancer drugs market.
-
Which was the leading molecule type for anal cancer pipeline drugs in 2023?
In 2023, the leading molecule type for anal cancer pipeline drugs was biologics.
-
Which was the leading RoA for anal cancer pipeline drugs in 2023?
Most pipeline drugs that were under development for anal cancer were injection therapies in 2023.
-
Who are the top sponsors in anal cancer marketed and pipeline drugs market?
A few of the top sponsors in anal cancer marketed and pipeline drugs market are National Cancer Institute, the US, Merck & Co Inc., Incyte Corp., Molecular Partners AG, and Xencor Inc., among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.